Richard F Clark

USPTO Granted Patents = 32 (Patent Applications = 8)

CIPO Patents = 2 (Patent Applications = 14)

EPO Patents = 2 (Patent Applications = 13)

Average Co-Inventor Count = 5.3

ph-index = 9

Forward Citations = 259(Granted Patents)

Location History:

Bettendorf, IA (US) (1980)
Mundelin, IL (US) (2000)
Mundelein, IL (US) (1998 - 2007)
Eden, NY (US) (2008)
Gurnee, IL (US) (2004 - 2018)

Company Filing History:

17 out of 4,177

Abbott Laboratories Corporation

4. 2 out of 832,680

Other

patents

Years Active: 1980-2018

Loading Chart...

32 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 9957274 - Indane inhibitors of EED and methods of their use (2018-05-01),

2. 9796708 - Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors (2017-10-24),

3. 9758511 - NAMPT inhibitors (2017-09-12),

4. 9302989 - NAMPT and rock inhibitors (2016-04-05),

5. 9296723 - NAMPT inhibitors (2016-03-29),

6. 9193723 - NAMPT inhibitors (2015-11-24),

7. 9187472 - NAMPT inhibitors (2015-11-17),

8. 9051315 - Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition (2015-06-09),

9. 8975398 - NAMPT inhibitors (2015-03-10),

10. 8748627 - Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome (2014-06-10),

11. 8691810 - Pyrrolopyridine and pyrrolopyrimidine inhibitors of kinases (2014-04-08),

12. 8536180 - Pyrimidine inhibitors of kinase activity (2013-09-17),

13. 8354422 - Pyrimidine inhibitors of kinase activity (2013-01-15),

14. 8163769 - Antibacterial compounds (2012-04-24),

15. 8067409 - Protein kinase inhibitors (2011-11-29),

Title: The Innovative Contributions of Richard F. Clark

Introduction

Richard F. Clark, based in Gurnee, Illinois, is a well-respected inventor with an impressive portfolio of 31 patents. His work has significantly impacted the pharmaceutical industry, particularly in the development of innovative treatments for serious health conditions, including various forms of cancer.

Latest Patents

Among Richard F. Clark's latest patents, two stand out for their potential therapeutic applications. The first patent details Indane inhibitors of EED and their methods of use. These compounds have a specific structural formula, allowing for the treatment of various diseases related to EED, including cancer, through the administration of these innovative compounds.

His second notable patent revolves around Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors. This invention discloses a range of compounds characterized by a defined structural formula capable of serving as effective agents in treating diseases, notably cancer. The associated pharmaceutical compositions also encompass one or more of these compounds, showcasing Clark’s commitment to advancing medical science through his innovations.

Career Highlights

Richard F. Clark has built a distinguished career, contributing to prominent organizations like Abbott Laboratories Corporation and AbbVie Inc. His roles within these companies have provided him with a platform to develop groundbreaking therapeutic solutions and solidified his status as a leading inventor in the pharmaceutical field.

Collaborations

Throughout his career, Richard has collaborated with notable colleagues, including Yat Sun Or and Zhenkun Ma. These partnerships have facilitated the exchange of ideas and innovation, leading to significant advancements in their shared fields of research.

Conclusion

Richard F. Clark's extensive patent portfolio and collaboration with esteemed colleagues highlight his substantial contributions to medical research and innovation. His inventions pave the way for the development of new therapies, demonstrating the vital role of inventors in addressing pressing health challenges. With each patent, Clark continues to make an indelible mark on the world of pharmaceuticals.

This text is generated by artificial intelligence and may not be accurate.